Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.

Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI.

J Affect Disord. 2019 Sep 3;260:131-139. doi: 10.1016/j.jad.2019.09.017. [Epub ahead of print]

PMID:
31494365
2.

Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care - The reality of treatment resistant-based therapies.

Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B.

J Psychiatr Res. 2019 Jul;114:211-213. doi: 10.1016/j.jpsychires.2019.04.027. Epub 2019 Apr 27. No abstract available.

PMID:
31101328
3.

Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.

Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B.

J Psychiatr Res. 2019 Apr;111:59-67. doi: 10.1016/j.jpsychires.2019.01.003. Epub 2019 Jan 4.

4.

Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.

Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M.

J Psychiatr Res. 2019 Mar;110:166-171. doi: 10.1016/j.jpsychires.2019.01.010. Epub 2019 Jan 8.

PMID:
30641350
5.

Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI.

Mol Psychiatry. 2019 Jan 7. doi: 10.1038/s41380-018-0311-2. [Epub ahead of print]

PMID:
30617276
6.

Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.

Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI.

Depress Anxiety. 2019 Mar;36(3):235-243. doi: 10.1002/da.22875. Epub 2018 Dec 30.

PMID:
30597688
7.

2018 American Society of Consultant Pharmacists Annual Meeting & Exhibition.

Bridgeman M, Prete D, Rolston N, Abazia D, Sturgill M, Finn L, Summers D, Marvanova M, Henkel P, Thompson J, Dewey M, Friesner D, Marvanova M, Alessi C, Cuellar L, Yamagishi L, O'Neil C, Erickson O, Mazzei K, Kamal K, Early N, Bainter B, Hanson L, Schmitz E, Loomis A, Norberto M, Hume A, Meyer M, Batra R, Likar D, Enguidanos S, Liu C, Kotansky B, Fisher A, Ruby CM, Pruskowski J, Karim SNA, Yong BSW, Alessi C, Cuellar L, Slattum P, Crouse E, Delafuente J, Donohoe K, Ogbonna K, Peron E, Powers K, Price E, Zimmerman K, Rahim S, Gendron T, Slattum P, Donohoe K, Cho C, Zimmerman K, Crouse E, Peron E, Powers K, Price E, Slattum P, Donohoe K, Elliott L, Minter C, Morin M, Marshall L, Stevens G, Cordaro C, Hill M, Nagy K, Kroustos KR, Sobota KF, Mahan R, Bailey T, Ioannou K, Mansour D, Thompson T, Chatellier K, Schwenk A, Ruby C, Chen TS, Li S, James M, Spilios M, Leschak A, Levine A, Forgette S, Oluigbo N, Szollosi D, Avalime D, Weaver SB, Maneno M, Ettienne E, Yi JY, Hart L, Gray S, Ozalas S, Miller K, Dave R, Bork J, Emmelhainz J, Adams K, Postolski J, Willoughby M, Feldman E, Braham K, Miller C, Barbagallo D, Seabury R, Noviasky J, Alessi C, Cuellar L, Dabhi J, Bartlett D, Le T, Simoni-Wastila L, Kuzucan A, Simoni-Wastila L, Le T, Park S, Simoni-Wastila L, Le T, Park S, Choi M, Simoni-Wastila L, Park S, Le T, Choi M, Simoni-Wastila L, Khokhar B, Choi M, Le T, Simoni-Wastila L, Brody P, Hejna M, Mason J, Graham M, Micceri J, Lypska R, Quinn B, Wilson H, Wahler R, Aloyo M, Tomm V, Hill A, Obringer A, Butterfoss K, Blak J, Balcer R, Boza J, Foster A, Shafique E, Kleven C, Wigle P, Brown B, Alessi C, Cuellar L, Meyer K, Mobley-Bukstein W, Singh H, Perez E, Mira AE, Kuehner W, Czechowski L, Cook H, Brandt N, Parson J, Fornaro R, Brandt N, Claeys K, Zarowitz B, Mansour D, McFadden C, Simpkins S, Ojowa F, Klutts A, Holmes S, Smith E, Cornman JR, Doran K, Resnick B, Brandt N, Umeozulu C, Williams A, Brandt N, Hennawi G, Thomas D, Gerber DK, Meyer K, Sharma K, Cooke C, Howard A, Chater R, Vogler A, Brandt N, Kennett-Hayes K, Elliott L, Engelbert J, Hargrave E, Bambico C, Patel K, Warriner C, Slattum P, Desai NR, Rowan CG, Alvarez P, Fogli J, Toto RD, Desai NR, Alvarez P, Fogli J, Reed P, Owens MK, Greden JF, Rothschild AJ, Zandy S, Thase M, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Li J, Gilbert A, Burns L, Jablonski M, Dechairo B, Parikh S, Donohue J, Feldman G, Sethi S, Barnes C, Pendyala S, Bourdet D, Ferguson G, Barnes C, Pendyala S, Crater G, Fogli J, Mayo M, Gross C, Miyawa J, Ono R, Woods S, Garza D, Panov N, Fogli J, Moran E, Sabesan V, Wertman J, Ngim K.

Consult Pharm. 2017 Oct 1;33(10):572-608.

PMID:
30322434
8.

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI.

Mol Psychiatry. 2018 Oct 3. doi: 10.1038/s41380-018-0256-5. [Epub ahead of print] Erratum in: Mol Psychiatry. 2019 Jan 7;:.

9.

Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.

O'Connell CP, Goldstein-Piekarski AN, Nemeroff CB, Schatzberg AF, Debattista C, Carrillo-Roa T, Binder EB, Dunlop BW, Craighead WE, Mayberg HS, Williams LM.

Am J Psychiatry. 2018 Mar 1;175(3):251-261. doi: 10.1176/appi.ajp.2017.17020172. Epub 2017 Dec 15.

10.

Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial.

Holtzheimer PE, Husain MM, Lisanby SH, Taylor SF, Whitworth LA, McClintock S, Slavin KV, Berman J, McKhann GM, Patil PG, Rittberg BR, Abosch A, Pandurangi AK, Holloway KL, Lam RW, Honey CR, Neimat JS, Henderson JM, DeBattista C, Rothschild AJ, Pilitsis JG, Espinoza RT, Petrides G, Mogilner AY, Matthews K, Peichel D, Gross RE, Hamani C, Lozano AM, Mayberg HS.

Lancet Psychiatry. 2017 Nov;4(11):839-849. doi: 10.1016/S2215-0366(17)30371-1. Epub 2017 Oct 4.

PMID:
28988904
11.

Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression.

Williams LM, Debattista C, Duchemin AM, Schatzberg AF, Nemeroff CB.

Transl Psychiatry. 2016 May 3;6:e799. doi: 10.1038/tp.2016.61.

12.

Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report.

van Dinteren R, Arns M, Kenemans L, Jongsma ML, Kessels RP, Fitzgerald P, Fallahpour K, Debattista C, Gordon E, Williams LM.

Eur Neuropsychopharmacol. 2015 Nov;25(11):1981-90. doi: 10.1016/j.euroneuro.2015.07.022. Epub 2015 Aug 6.

PMID:
26282359
13.

Frontal and rostral anterior cingulate (rACC) theta EEG in depression: implications for treatment outcome?

Arns M, Etkin A, Hegerl U, Williams LM, DeBattista C, Palmer DM, Fitzgerald PB, Harris A, deBeuss R, Gordon E.

Eur Neuropsychopharmacol. 2015 Aug;25(8):1190-200. doi: 10.1016/j.euroneuro.2015.03.007. Epub 2015 Apr 20.

PMID:
25936227
14.

ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.

Schatzberg AF, DeBattista C, Lazzeroni LC, Etkin A, Murphy GM Jr, Williams LM.

Am J Psychiatry. 2015 Aug 1;172(8):751-9. doi: 10.1176/appi.ajp.2015.14050680. Epub 2015 Mar 27.

PMID:
25815420
15.

Cognitive and emotional biomarkers of melancholic depression: An iSPOT-D report.

Day CV, Gatt JM, Etkin A, DeBattista C, Schatzberg AF, Williams LM.

J Affect Disord. 2015 May 1;176:141-50. doi: 10.1016/j.jad.2015.01.061. Epub 2015 Feb 7.

PMID:
25710095
16.

The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment.

Saveanu R, Etkin A, Duchemin AM, Goldstein-Piekarski A, Gyurak A, Debattista C, Schatzberg AF, Sood S, Day CV, Palmer DM, Rekshan WR, Gordon E, Rush AJ, Williams LM.

J Psychiatr Res. 2015 Feb;61:1-12. doi: 10.1016/j.jpsychires.2014.12.018. Epub 2014 Dec 31.

PMID:
25586212
17.

Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report.

Day CV, John Rush A, Harris AW, Boyce PM, Rekshan W, Etkin A, DeBattista C, Schatzberg AF, Arnow BA, Williams LM.

J Affect Disord. 2015 Mar 15;174:493-502. doi: 10.1016/j.jad.2014.10.046. Epub 2014 Nov 7.

PMID:
25554994
18.

ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression.

Ray A, Tennakoon L, Keller J, Sarginson JE, Ryan HS, Murphy GM, Lazzeroni LC, Trivedi MH, Kocsis JH, DeBattista C, Schatzberg AF.

Pharmacogenomics J. 2015 Aug;15(4):332-9. doi: 10.1038/tpj.2014.72. Epub 2014 Dec 9.

PMID:
25487678
19.

Spiritual coping of older persons in Malta and Australia (part 2).

Baldacchino DR, Bonello L, Debattista CJ.

Br J Nurs. 2014 Aug 12;23(15):843-6. doi: 10.12968/bjon.2014.23.15.843.

PMID:
25119325
20.

Spiritual coping of older people in Malta and Australia (part 1).

Baldacchino DR, Bonello L, Debattista CJ.

Br J Nurs. 2014 Jul 24-Aug 13;23(14):792-9. doi: 10.12968/bjon.2014.23.14.792.

PMID:
25062315
21.

Spiritual coping in rehabilitation- a comparative study: part 2.

Baldacchino D, Torskenaes K, Kalfoss M, Borg J, Tonna A, Debattista C, Decelis N, Mifsud R.

Br J Nurs. 2013 Apr 11-24;22(7):402-8.

PMID:
23588017
22.

Spiritual coping in rehabilitation - a comparative study: part 1.

Baldacchino D, Torskenaes K, Kalfoss M, Borg J, Tonna A, Debattista C, Decelis N, Mifsud R.

Br J Nurs. 2013 Feb 28-Mar 13;22(4):228-32.

PMID:
23448986
23.

Measuring severe adverse events and medication selection using a "PEER Report" for nonpsychotic patients: a retrospective chart review.

Hoffman DA, Debattista C, Valuck RJ, Iosifescu DV.

Neuropsychiatr Dis Treat. 2012;8:277-84. doi: 10.2147/NDT.S31665. Epub 2012 Jun 21.

24.

The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression.

DeBattista C, Kinrys G, Hoffman D, Goldstein C, Zajecka J, Kocsis J, Teicher M, Potkin S, Preda A, Multani G, Brandt L, Schiller M, Iosifescu D, Fava M.

J Psychiatr Res. 2011 Jan;45(1):64-75. doi: 10.1016/j.jpsychires.2010.05.009. Epub 2010 Jul 3.

PMID:
20598710
25.
26.

Utility of atypical antipsychotics in the treatment of resistant unipolar depression.

DeBattista C, Hawkins J.

CNS Drugs. 2009;23(5):369-77. doi: 10.2165/00023210-200923050-00002. Review.

PMID:
19453199
27.

A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction.

Blasey CM, Debattista C, Roe R, Block T, Belanoff JK.

Contemp Clin Trials. 2009 Jul;30(4):284-8. doi: 10.1016/j.cct.2009.03.001. Epub 2009 Mar 24. Erratum in: Contemp Clin Trials. 2009 Sep;30(5):497. Contemp Clin Trials. 2010 Jan;31(1):134.

PMID:
19318138
28.

Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function.

Gomez RG, Posener JA, Keller J, DeBattista C, Solvason B, Schatzberg AF.

Psychoneuroendocrinology. 2009 Aug;34(7):1012-8. doi: 10.1016/j.psyneuen.2009.01.017. Epub 2009 Mar 3.

PMID:
19261389
29.

Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial.

Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S.

JAMA. 2008 Jul 23;300(4):395-404. doi: 10.1001/jama.300.4.395.

PMID:
18647982
30.

Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness.

Fava M, Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ.

Ann Clin Psychiatry. 2007 Jul-Sep;19(3):153-9.

PMID:
17729016
31.

Depression and smoking cessation: does the evidence support psychiatric practice?

Lembke A, Johnson K, DeBattista C.

Neuropsychiatr Dis Treat. 2007 Aug;3(4):487-93.

32.

Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.

DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G.

Biol Psychiatry. 2006 Dec 15;60(12):1343-9. Epub 2006 Aug 4.

PMID:
16889757
33.

The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.

Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK.

Behav Brain Res. 2006 Aug 10;171(2):225-9. Epub 2006 Jun 19.

PMID:
16782211
34.

Augmentation and combination strategies for depression.

DeBattista C.

J Psychopharmacol. 2006 May;20(3 Suppl):11-8.

PMID:
16644767
35.

The use of mifepristone in the treatment of neuropsychiatric disorders.

DeBattista C, Belanoff J.

Trends Endocrinol Metab. 2006 Apr;17(3):117-21. Epub 2006 Mar 10. Review. Erratum in: Trends Endocrinol Metab. 2006 Dec;17(10):389.

PMID:
16530421
36.
37.

The neuropsychological profile of psychotic major depression and its relation to cortisol.

Gomez RG, Fleming SH, Keller J, Flores B, Kenna H, DeBattista C, Solvason B, Schatzberg AF.

Biol Psychiatry. 2006 Sep 1;60(5):472-8. Epub 2006 Feb 17.

PMID:
16483550
38.

Update on augmentation of antidepressant response in resistant depression.

DeBattista C, Lembke A.

Curr Psychiatry Rep. 2005 Dec;7(6):435-40. Review.

PMID:
16318821
39.

Detecting psychotic major depression using psychiatric rating scales.

Keller J, Gomez RG, Kenna HA, Poesner J, DeBattista C, Flores B, Schatzberg AF.

J Psychiatr Res. 2006 Feb;40(1):22-9. Epub 2005 Sep 13.

PMID:
16165160
40.

The efficacy of divalproex sodium in the treatment of agitation associated with major depression.

Debattista C, Solomon A, Arnow B, Kendrick E, Tilston J, Schatzberg AF.

J Clin Psychopharmacol. 2005 Oct;25(5):476-9.

PMID:
16160625
41.

A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction.

DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E.

J Clin Psychiatry. 2005 Jul;66(7):844-8.

PMID:
16013899
42.

C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease.

DeBattista C, Belanoff J.

Curr Alzheimer Res. 2005 Apr;2(2):125-9. Review.

PMID:
15974908
43.

Executive dysfunction in major depressive disorder.

DeBattista C.

Expert Rev Neurother. 2005 Jan;5(1):79-83. Review.

PMID:
15853477
45.

HPA axis activation in major depression and response to fluoxetine: a pilot study.

Young EA, Altemus M, Lopez JF, Kocsis JH, Schatzberg AF, DeBattista C, Zubieta JK.

Psychoneuroendocrinology. 2004 Oct;29(9):1198-204.

PMID:
15219644
46.

A prospective trial of modafinil as an adjunctive treatment of major depression.

DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J.

J Clin Psychopharmacol. 2004 Feb;24(1):87-90.

PMID:
14709953
47.

Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.

DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR; Modafinil in Depression Study Group.

J Clin Psychiatry. 2003 Sep;64(9):1057-64.

PMID:
14628981
48.

Seizure duration with remifentanil/methohexital vs. methohexital alone in middle-aged patients undergoing electroconvulsive therapy.

Smith DL, Angst MS, Brock-Utne JG, DeBattista C.

Acta Anaesthesiol Scand. 2003 Oct;47(9):1064-6.

PMID:
12969096
49.

Safety of antidepressants in the elderly.

Sommer BR, Fenn H, Pompei P, DeBattista C, Lembke A, Wang P, Flores B.

Expert Opin Drug Saf. 2003 Jul;2(4):367-83. Review.

PMID:
12904093
50.

Supplemental Content

Loading ...
Support Center